Kodiak Sciences (MEX:KOD) Other Current Liabilities: MXN0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:KOD Kodiak Sciences Inc MEX:KOD
27 GF Score
Price MXN749.00
! 4 Warning Signs
View Full Analysis

What is Kodiak Sciences Other Current Liabilities?

Kodiak Sciences MEX:KOD 27 Other Current Liabilities is MXN0.00 Mil as of Mar. 2026. GuruFocus rates MEX:KOD with a GF Score™ of 27/100. The stock has 4 warning signs investors should review.

Kodiak Sciences's other current liabilities for the quarter that ended in Mar. 2026 was MXN0.00 Mil.

Kodiak Sciences's quarterly other current liabilities increased from Sep. 2025 (MXN0.00 Mil) to Dec. 2025 (MXN0.00 Mil) but then declined from Dec. 2025 (MXN0.00 Mil) to Mar. 2026 (MXN0.00 Mil).

Kodiak Sciences's annual other current liabilities increased from Dec. 2023 (MXN0.00 Mil) to Dec. 2024 (MXN0.00 Mil) but then declined from Dec. 2024 (MXN0.00 Mil) to Dec. 2025 (MXN0.00 Mil).

Kodiak Sciences Other Current Liabilities Related Terms

Kodiak Sciences Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Kodiak Sciences's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kodiak Sciences Other Current Liabilities Chart

Kodiak Sciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.00 0.00 0.00 0.00 0.00

Kodiak Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
MEX:KOD
27GF Score
Kodiak Sciences Inc MEX:KOD
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kodiak Sciences Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of MXN0.00 Mil mean?
Kodiak Sciences (MEX:KOD) has a Other Current Liabilities of MXN0.00 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Kodiak Sciences.
Is Kodiak Sciences' Other Current Liabilities too high?
Kodiak Sciences' current Other Current Liabilities is MXN0.00 Mil. Overall, Kodiak Sciences has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Kodiak Sciences' Other Current Liabilities compare to ABCL and AGIO?
Kodiak Sciences' Other Current Liabilities of MXN0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Kodiak Sciences. Kodiak Sciences's current Other Current Liabilities is MXN0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kodiak Sciences stock overvalued right now?
Kodiak Sciences (MEX:KOD) has a current Other Current Liabilities of MXN0.00 Mil. The current Other Current Liabilities is MXN0.00 Mil. Kodiak Sciences' overall GF Score™ is 27/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Kodiak Sciences (MEX:KOD), the current Other Current Liabilities is MXN0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kodiak Sciences Business Description

Other Exchanges KOD:USAK27:Germany
Address 1250 Page Mill Road, Palo Alto, CA, USA, 94304
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.
27GF Score

Get the complete analysis for MEX:KOD

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN749.00
Price